Development and validation of reversed phase high performance liquid chromatographic method for determination of moxonidine in the presence of its impurities
Svetlana Milovanović, Biljana Otašević, Mira Zečević, Ljiljana Živanović, Ana Protić, Svetlana Milovanović, Biljana Otašević, Mira Zečević, Ljiljana Živanović, Ana Protić
Index: J. Pharm. Biomed. Anal. 59 , 151-6, (2012)
Full Text: HTML
Abstract
Highlights ► Moxonidine is a second-generation centrally acting antihypertensive drug. ► An isocratic RP–HPLC method was developed for the analysis of moxonidine and its impurities. ► Central composite design and response surface methodology were used as statistical tools. ► Statistical tools were applied in method development and robustness testing.
Related Compounds
Related Articles:
2004-03-01
[Curr. Med. Res. Opin. 20(3) , 359-67, (2004)]
Moxonidine: a review of safety and tolerability after seven years of clinical experience.
1999-08-01
[J. Hypertens. 17 , S37-S39, (1999)]
[The efficacy of antihypertension drugs and their combinations in the non-treated hypertension].
2013-01-01
[Med. Tr. Prom. Ekol. (5) , 7-11, (2013)]
2012-11-01
[Surg. Today 42(11) , 1051-60, (2012)]
Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
2013-09-01
[Am. J. Cardiol. 112(5) , 684-7, (2013)]